Earnings season marches on, and we're here to spotlight the companies set to unveil their financial results in the next trading day. As Friday approaches, investors are eagerly anticipating reports ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AbbVie in a report released on Tuesday, ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...